12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ICES13: Phase III started

Innovacell began a double-blind, placebo-controlled, European Phase III trial to evaluate a single dose of ICES13 in 370 patients....

Read the full 72 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >